The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which combines semaglutide with dual amylin and calcitonin receptor agonist ...

Zealand and Roche will co-develop and co-commercialise Zealand’s amylin analogue petrelintide as a monotherapy, and in combination therapies. The first planned combination will pair petrelintide with ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

While GLP-1RAs such as semaglutide work by stimulating insulin secretion, reducing glucagon levels, and slowing gastric emptying, amylin analogues such as petrelintide act through a different ...

The market is evolving from GLP-1s to GLP-1/GIPs, to so-called triple Gs (GLP1/GIP/glucagon) like Eli Lilly’s tirzepatide, amylin analogs, GLP-1/amylin analogs, GLP1/GIP-amylin analogs ...

CagriSema consists of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). The combination works by decreasing hunger and increasing ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...